Tian'an Pharmaceutical Co., Ltd.

OTCPK:TNPH Stock Report

Market Cap: US$425.0k

Tian'an Pharmaceutical Valuation

Is TNPH undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of TNPH when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate TNPH's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate TNPH's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for TNPH?

Key metric: As TNPH is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for TNPH. This is calculated by dividing TNPH's market cap by their current book value.
What is TNPH's PB Ratio?
PB Ration/a
BookUS$14.43m
Market CapUS$424.97k

Price to Book Ratio vs Peers

How does TNPH's PB Ratio compare to its peers?

The above table shows the PB ratio for TNPH vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average0.2x
KDCE Kid Castle Educational
0.1xn/aUS$357.2k
ACAN AmeriCann
0.09xn/aUS$465.9k
SPRC SciSparc
0.1x63.0%US$768.3k
TFFP TFF Pharmaceuticals
0.5xn/aUS$1.5m
TNPH Tian'an Pharmaceutical
n/an/aUS$425.0k

Price-To-Book vs Peers: Insufficient data to calculate TNPH's Price-To-Book Ratio vs. peers for valuation analysis.

Price to Book Ratio vs Industry

How does TNPH's PB Ratio compare vs other companies in the US Pharmaceuticals Industry?

25 CompaniesPrice / BookEstimated GrowthMarket Cap
TNPH is unprofitableIndustry Avg. 1.8xNo. of Companies28PB01.22.43.64.86+
25 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: Insufficient data to calculate TNPH's Price-To-Book Ratio vs. industry for valuation analysis.

Price to Book Ratio vs Fair Ratio

What is TNPH's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

TNPH PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ration/a
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate TNPH's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

BeiGene

US$21.9b

An oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally.

BGNE

US$206.16

7D

8.2%

1Y

10.0%

Collegium Pharmaceutical

US$990.4m

A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

COLL

US$30.71

7D

2.5%

1Y

20.0%

IQVIA Holdings

US$36.6b

Engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific.

IQV

US$201.43

7D

-0.2%

1Y

-7.1%